<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01160315</url>
  </required_header>
  <id_info>
    <org_study_id>ErasmeUH</org_study_id>
    <nct_id>NCT01160315</nct_id>
  </id_info>
  <brief_title>Efficiency of Gonadotropin-releasing Hormone (GnRH) Agonist in Preventing Chemotherapy Induced Ovarian Failure</brief_title>
  <acronym>Erasme-POF</acronym>
  <official_title>A Prospective Open Randomized Trial on the Efficacy of Gonadotropin-releasing Hormone Agonist Depot-Triptorelin- to Prevent Chemotherapy Induced Premature Ovarian Failure in Lymphoma Patients.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Erasme University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Fonds National de la Recherche Scientifique</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ipsen</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Erasme University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Chemotherapy drugs like alkylating agents are frequently used in various combined regimens to
      treat neoplastic and benign diseases. These drugs are definitely associated with premature
      ovarian failure (POF), resulting in an important decrease of the long-term quality of life
      and an increase of morbidity. A recent study showed that the patients treated by alkylating
      agents had a 4.52 fold higher risk to lose their ovarian function compared with those who
      were treated by other agents. The rate of POF after treatment ranged from 40 to 80%,
      according to the age of the patients and the total doses administered.

      Young women who experience POF have to face with the prospects of infertility and to consider
      years of hormonal replacement therapy. The possibility of minimizing gonadal damage by
      administering of protective therapy during chemotherapy represents an attractive option for
      these patients.

      The aim of this study is to evaluate the protective effect on the ovarian function of the
      gonadotropin-releasing hormone agonist (GnRha) administered concomitantly to alkylating
      agents. Preliminary data in the literature on animals (rat and monkeys) are promising. Data
      in human are, however, highly controversial.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2002</start_date>
  <completion_date type="Actual">October 2015</completion_date>
  <primary_completion_date type="Actual">June 2010</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Premature ovarian failure rate</measure>
    <time_frame>5 years</time_frame>
    <description>Primary endpoint is to evaluate the short and long-term efficacy of triptorelin depot plus progestin versus progestin alone to prevent POF induced by chemotherapy treatment. The ovarian function (FSH, E2, Progesterone, and AMH, presence of spontaneous menstrual cycle and pregnancies) will be evaluated every 3 months during the first 6 months after the end of chemotherapy, every 6 months during the next 18 months and once a year during an additional 5 years. All hormonal treatment has to be interrupted 10 days before the blood test.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Impact of the flare-up effect of Triptorelin</measure>
    <time_frame>2 years</time_frame>
    <description>The Triptorelin/Norethisterone treatment has to start if possible 10 days before the beginning of the chemotherapy (time necessary to obtain the inhibitory effect of the Gn-Rha on the ovarian function)and at least the same day. The impact of the interval between the triptorelin/noresthisterone treatment and the start of the chemotherapy on the efficacy to protect ovarian function (FSH level at 2 years of follow-up) will be evaluated.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ovarian function during the treatment</measure>
    <time_frame>1 year</time_frame>
    <description>Evaluation of the inhibitory action of the treatment on ovarian function during the chemotherapy: the hormonal profile (FSH and estradiol levels) will be evaluated 10 days after the triptorelin/Norethisterone treatment start, before the second injection (3 months) and at the end of the chemotherapy. Adverse effects due to the injection are evaluated 7-10 days after each injection.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with Adverse Events as a Measure of Safety and Tolerability</measure>
    <time_frame>1 year</time_frame>
    <description>Anamnesis including the compliance of the treatment (possible treatment interruption or dosage modification) and the adverse events are performed at each visit. All events expected and directly related to the chemotherapy or the initial pathology will be documented in the Case Report Form adverse events. Specific anamnesis concerning the possible adverse events due to treatment must be completed for each follow-up visit.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Add back therapy effect</measure>
    <time_frame>1 year</time_frame>
    <description>Evaluation of the efficacy of concomitant administration of progestin alone as &quot;Add Back Therapy&quot; during the treatment: specific anamnesis including estrogen-deficiency symptoms (hot flushes, vaginal dryness...) is reported at each visit during the treatment. Osteodensitometry is performed after 1 year follow-up.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">118</enrollment>
  <condition>Fertility Preservation</condition>
  <condition>Alkylating Agents</condition>
  <condition>Lymphoma</condition>
  <arm_group>
    <arm_group_label>Arm A (GnRha arm)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>IM injection of Triptorelin -Decapeptyl PR 11.25mg- (every 3 months) and Norethisterone acetate- Primolut-Nor 5 mg- per os continuously until the end of the chemotherapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B (control Arm)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Norethisterone acetate alone, 5mg par day, (ARM B) until the end of the chemotherapy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Triptorelin</intervention_name>
    <description>Triptorelin: intramusculAR injection every 3 months</description>
    <arm_group_label>Arm A (GnRha arm)</arm_group_label>
    <other_name>Decapeptyl</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Norethisterone acetate</intervention_name>
    <description>5 mg/day per os until during chemotherapy</description>
    <arm_group_label>Arm A (GnRha arm)</arm_group_label>
    <arm_group_label>Arm B (control Arm)</arm_group_label>
    <other_name>Primolut</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Women between 18 and 45 years old with lymphoma.

          -  Menarche &gt;2year

          -  Subject treated by chemotherapy-induced ovarian failure including alkylant agents
             (except less than 8 ABVD)

          -  Presence of both ovaries (ovarian biopsy or hemiovariectomy for cryopreservation
             before treatment is accepted).

          -  Ability to give written informed consent

        Exclusion Criteria:

          -  Hormonal-sensible malignancy

          -  Chemotherapy or radiotherapy before the inclusion in the study

          -  Pelvic irradiation including the ovaries or TBI

          -  Pregnancy

          -  Patient weight above 110 kg

          -  Anamnesis of thrombo-embolic processes

          -  Severe hepatic or renal insufficiency

          -  Systolic blood pressure &gt;15mmHg or diastolic blood pressure &gt; 90mmHg

          -  Contraindication of IM injection

          -  Relevant ovarian abnormalities (Functional follicular cyst are tolerated)

          -  Anamnesis of premature ovarian failure or irregular cycle (repeated amenorrhoea &gt;2
             months)

          -  Dubin-Johnson and Rotor Syndrome
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yvon Englert, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Erasme Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Algemeen Ziekenhuis Stuivenberg</name>
      <address>
        <city>Antwerpen</city>
        <zip>2060</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AZ St Jan</name>
      <address>
        <city>Brugges</city>
        <zip>8000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bordet</name>
      <address>
        <city>Brussels</city>
        <zip>1000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Erasme Hospital</name>
      <address>
        <city>Brussels</city>
        <zip>1070</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AZ-VUB</name>
      <address>
        <city>Brussels</city>
        <zip>1090</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St Luc University</name>
      <address>
        <city>Brussels</city>
        <zip>1200</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHRU Lille</name>
      <address>
        <city>Lille</city>
        <zip>59037</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Dijon</name>
      <address>
        <city>Dijon</city>
        <zip>21034</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Nancy</name>
      <address>
        <city>Nancy</city>
        <zip>54511</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Henry-Mondor Hospital</name>
      <address>
        <city>Paris-Creteil</city>
        <zip>94010</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>HÃ´pital Hotel Dieu</name>
      <address>
        <city>Paris</city>
        <zip>75004</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St Louis Hospital</name>
      <address>
        <city>Paris</city>
        <zip>75475</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU St Antoine</name>
      <address>
        <city>Paris</city>
        <zip>75571</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Henri Beckerel</name>
      <address>
        <city>Rouen</city>
        <zip>76038</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instituto Europeo di oncologia</name>
      <address>
        <city>Milano</city>
        <zip>1-20141</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>France</country>
    <country>Italy</country>
  </location_countries>
  <verification_date>October 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 7, 2010</study_first_submitted>
  <study_first_submitted_qc>July 9, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 12, 2010</study_first_posted>
  <last_update_submitted>October 29, 2015</last_update_submitted>
  <last_update_submitted_qc>October 29, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 30, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>ovarian failure, chemotherapy, lymphoma, GnRH agonist</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hormones</mesh_term>
    <mesh_term>Triptorelin Pamoate</mesh_term>
    <mesh_term>Norethindrone</mesh_term>
    <mesh_term>Norethindrone acetate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

